DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.05 Bil PE Ratio: 47.26 PB Ratio: 15.58 GF Score: 74/100

DexCom Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 12, 2020 / 01:30PM GMT
Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst

Good morning, everybody, and welcome to the 40th Annual Canaccord Genuity Global Growth Conference. My name is Kyle Rose. I'm one of the medical device analysts here at Canaccord Genuity, and I'm very pleased to be joined by DexCom this morning.

Presenting on behalf of DexCom or participating in this fireside chat on behalf of DexCom today is Steve Pacelli, Executive Vice President of Strategy and Corporate Development; as well as Quentin Blackford, the CFO and COO. And we'll also be joined, I think, by a couple of team members for the second half. So we've got a fireside chat here in the first portion followed by a continuation and a bit of a breakout in the second part.

So before we begin, I just want to remind everybody to seek out any potential relevant disclosures. Those can be found on either our conference or our firm website.

So with that, let's kick it off. There's been a lot going on right now, a lot that I think makes diabetes a really interesting sector. And with DexCom specifically when

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot